COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,283 Articles (22,759 medRxiv, 8,524 bioRxiv)

Most recent first Previous |  Page 915: Articles 9141-9150  | Next

Biophysical fitness landscape of the SARS-CoV-2 Delta variant receptor binding domain
Patrick, C., Upadhyay, V., Lucas, A., Mallela, K.
10.1101/2022.02.21.481311 — Posted: 2022-02-23
Confirming Multiplex Q-PCR Use in COVID-19 with Next Generation Sequencing: Strategies for Epidemiological Advantage
Carpenter, R. E., Tamrakar, V. K., Chahar, H. S., Vine, T., Sharma, R.
10.1101/2022.02.22.481485 — Posted: 2022-02-23
Potent Neutralizing Activity of Polyclonal Equine Antibodies against Omicron SARS-CoV-2
Luczkowiak, J., Radreau, P., Nguyen, L., Labiod, N., Lasala, F., Herbreteau-Delale, C., Delgado, R.
10.1101/2022.02.21.481341 — Posted: 2022-02-23
Serological screening in wild ruminants in Germany, 2021/22: No evidence of SARS-CoV-2, bluetongue virus or pestivirus spread but high seroprevalences against Schmallenberg virus
Wernike, K., Fischer, L., Holsteg, M., Aebischer, A., Petrov, A., Marquart, K., Schotte, U., Schoen, J., Hoffmann, D., Hechinger, S., Neubauer-Juric, A., Blicke, J., Mettenleiter, T. C., Beer, M.
10.1101/2022.02.21.481262 — Posted: 2022-02-23
Mucosal Immunization of Cynomolgus Macaques with Adenoviral Vector Vaccine Elicits Neutralizing Nasal and Serum Antibody to Several SARS-CoV-2 Variants
Flitter, B. A., Lester, C. A., Tedjakusuma, S. N., Dora, E. G., Peinovich, N., Cortese, M., Martinez, C. I., Jegede, C. B., Neuhaus, E. D., Tucker, S. N.
10.1101/2022.02.21.481345 — Posted: 2022-02-23
SARS-CoV-2 Variant Delta Potently Suppresses Innate Immune Response and Evades Interferon-Activated Antiviral Responses
Tandel, D., Sah, V., Singh, N. K., Potharaju, P. S., Gupta, D., Shrivastava, S., Sowpati, D. T., Harshan, K. H.
10.1101/2022.02.22.481430 — Posted: 2022-02-23
An in-silico study of the mutation-associated effects on the spike protein of SARS-CoV-2, Omicron variant
Shishir, T. A., Jannat, T., Naser, I. B.
10.1101/2022.02.21.481269 — Posted: 2022-02-23
Cell-Mediated Immune Response after COVID 19 Vaccination in Patients with Inflammatory Bowel Disease
Caldera, F., Farraye, F., Necela, B., Cogen, D., Saha, S., Wald, A., Daoud, N., Chun, K., Grimes, I., Lutz, M., Swift, M. D., Virk, A., Bharucha, A. E., Patel, T., Gores, G. J., Chumsri, S., Hayney, M. S., Knuttson, K. L.
10.1101/2022.02.21.22271234 — Posted: 2022-02-23
Favourable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapies
QI, M., Le Bert, N., Chan, W., Tan, M., Hang, S. K., Hariharaputran, S., Sim, J. X. Y., Low, J., Ng, W. L., Wan, W. Y., Ang, T. L., Bertoletti, A., Salazar, E.
10.1101/2022.02.21.22271127 — Posted: 2022-02-23
Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study
Shehab, M., Alrashed, F., Abdullah, I., Alfadhli, A., Ali, H., Abu-farha, M., Channanath, A., Abubaker, J., Al-Mulla, F.
10.1101/2022.02.22.22271342 — Posted: 2022-02-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).